SELL with 50-70% trim before earnings; exit remaining position entirely if stock closes below $1,100; reload only after confirmed technical re-convergence (daily close above 10 EMA AND positive MACD histogram divergence AND stable/rising VWMA)

• Advocates 50-70% trim (more aggressive than Aggressive's 30-50%) to properly size position to risk asymmetry
• 78% beat probability does not equal 78% up probability—bar at $1T market cap is "beat by enough to justify valuation, raise guidance materially, and avoid warnings"
• Reload-on-confirmation thesis is dangerous; market may not give second entry at desired timeline
• 200 SMA at $1,024 is structural trend invalidation level—weekly close below would trigger sustained move lower
• Beta of 0.51 misunderstood by both Aggressive and Neutral—realized volatility around last three earnings prints was multiples of trailing beta
• Fundamentals (ROE 107.5%, operating margin expansion, revenue growth) already priced in at 32x book value and 40x trailing earnings
• Sequential revenue growth decelerated from plus 22% to plus 2.6% in five quarters—GLP-1 ramp maturing
• GLP-1 concentration risk: Mounjaro and Zepbound are entire thesis; pipeline assets (Olomorasib, Ratio Therapeutics) not near-term drivers
• 89% probability of no Fed rate cuts in 2026 supports higher-for-longer regime; Q2 S&P 500 profit growth easing
• A clean beat with soft guidance could deliver 5-8% drop; "meet" with cautious commentary could deliver double-digit move

→ vs aggressive: Proposed 30-50% trim is a half-measure—leaving 50-70% exposed to a binary event that could deliver 10-15% gap down is not risk management, it's a fig leaf of discipline

→ vs aggressive: Reload-on-confirmation thesis is a dangerous assumption—what if the stock gaps up and never fills, or gaps down through multiple technical levels?

→ vs neutral: Waiting for 10 EMA reclaim or breakdown below $1,100 before acting is paralysis at exactly the wrong moment—confirmation comes via drawdown, not signal

→ vs aggressive: Low beta framed as defensive profile with growth characteristics ignores that low beta also means limited recovery when company-specific catalysts hit

→ vs neutral: 200 SMA at $1,024 is the structural line in the sand—a weekly close below invalidates the entire multi-year uptrend

Trim 40-55% of existing LLY exposure before print; maintain core position; layer defined-risk hedge (collar or put spread) on remaining exposure; set stop at 1100 closing basis; do not initiate new capital until post-earnings confirmation (daily close above 10 EMA at 1168 with MACD histogram contraction and stable/rising VWMA)

• Technical setup is a correction within larger uptrend, not trend failure - lower Bollinger band at 1121.36 is real bounce zone with historical precedent; 200 SMA at 1024 is real structural floor
• Fundamentals are durable and underweighted by both sides - 107% ROE, margin expansion from 30% to 49% in three years, FCF inflection positive, capex peak approaching
• Forward P/E of 24.9x with EPS expected to nearly double makes valuation reasonable on PEG basis despite 32x book value trailing multiple
• Trim magnitude of 40-55% balances risk reduction with maintaining meaningful exposure to clean beat scenario; 30-50% was well-calibrated, 50-70% overshoots
• Collar or put spread financed by call sale provides asymmetric protection while keeping upside - uses full toolkit rather than trim-and-wait or trim-and-reload binary
• Stage trim timing - execute meaningful portion now to reduce event risk, reserve option to add back if price confirms lower band is holding over next 1-2 sessions
• Pipeline visibility with retatrutide, oral GLP-1, olomorasib (second FDA Breakthrough designation), and Kisunla supports fundamental bull case despite concentration risk in tirzepatide
• Macro environment supportive: Dow at record high, oil sliding, recession probability 8%, beta 0.51 supports relative outperformance for defensive growth name
• Both aggressive and conservative plans perform well on miss scenario but leave alpha on table - balanced plan participates in rerun, protects on miss, reduces variance on soft print
• Stop discipline: exit remaining position entirely on close below 1100 rather than averaging down; if print delivers with confirmation, reload to full position with hard stop at 200 SMA closing

→ vs aggressive: Selling into lower Bollinger band is selling the bottom of a two-day bounce zone statistically prone to mean-reversion; reload thesis treats uncertain re-entry as guaranteed conviction rather than hope

→ vs aggressive: Underweighted fundamental story - treating compounder with 107% ROE and multi-decade pipeline visibility as momentum trade ignores durable structural floor

→ vs conservative: Pushing for 50-70% trim is near-full exit framed as prudence - conflates trim with thesis abandonment; 70% reduction loses core conviction that justifies any position at all

→ vs conservative: Using trailing 32x book value as binary sell signal ignores forward P/E of 24.9x with EPS expected to nearly double - conflating trailing multiple with terminal multiple

→ vs conservative: Dismissed lower Bollinger band and 200 SMA as meaningful support levels when both are facts that argue for maintaining core exposure

→ vs conservative: Treating olomorasib as vaporware despite second FDA Breakthrough Therapy designation; pipeline is real and diversifying concentration risk